A5082147124- HIV/AIDS Research and Interventions
- Pneumocystis jirovecii pneumonia detection and treatment
- Tuberculosis Research and Epidemiology
- HIV/AIDS drug development and treatment
- HIV Research and Treatment
- Infectious Diseases and Tuberculosis
- Cytomegalovirus and herpesvirus research
- Immunodeficiency and Autoimmune Disorders
- HIV-related health complications and treatments
- Diagnosis and treatment of tuberculosis
- Parvovirus B19 Infection Studies
- Hepatitis C virus research
- Herpesvirus Infections and Treatments
- Respiratory viral infections research
- Pregnancy and Medication Impact
- Influenza Virus Research Studies
- Viral-associated cancers and disorders
- Mycobacterium research and diagnosis
- HIV, Drug Use, Sexual Risk
- Breastfeeding Practices and Influences
- Syphilis Diagnosis and Treatment
- Toxoplasma gondii Research Studies
- Hepatitis B Virus Studies
- Gestational Diabetes Research and Management
- Infant Nutrition and Health
Humboldt-Universität zu Berlin
1997-2025
Charité - Universitätsmedizin Berlin
2016-2025
Freie Universität Berlin
2017-2025
Stollery Children's Hospital
2021
University of Alberta
2021
University of California System
2019
University of California, San Francisco
2019
Johns Hopkins University
2019
Radboud University Nijmegen
2016
Radboud University Medical Center
2016
Zusammenfassung In Deutschland ist seit 2015 ein deutlicher Anstieg der gemeldeten Tuberkulosefälle zu verzeichnen. Zurückzuführen dieser vor allem auf die aktuell vermehrte Migration. Durch niedrige Inzidenz in den vorhergehenden Jahren konzentriert sich Erfahrung im Umgang mit Tuberkulose immer mehr spezialisierte Zentren. Pneumologen wie auch andere Fachbereiche sind nun aber wieder häufiger an Behandlung einer beteiligt, sodass Fachwissen zur Standardtherapie selteneren...
The pangenotypic regimen of glecaprevir and pibrentasvir (G/P) is approved to treat adults with chronic hepatitis C virus (HCV) infection has yielded high cure rates in clinical trials. Approved treatment options for pediatrics may include ribavirin. A pediatric patients remains an unmet need. DORA ongoing phase 2/3, nonrandomized, open-label study evaluating the pharmacokinetics (PK), safety, efficacy G/P HCV. This analysis includes Part 1 study, conducted adolescent 12-17 years age given...
Objective The aim of the study was to assess risk adverse pregnancy outcomes after antenatal antiretroviral therapy in a well‐defined prospective cohort nontransmitting HIV‐infected women. Methods Prospective monitoring 183 mother–child pairs from 13 centres Germany and Austria, delivering between 1995 2001, carried out. Following German–Austrian guidelines recommending an elective Caesarean section (CS) at 36 weeks, prematurity defined as <36 weeks' gestation for these analyses. Results...
Glecaprevir/pibrentasvir (GLE/PIB) has shown high efficacy and safety in chronic HCV-infected adults adolescents; data children were limited. DORA part 2 is a phase 2/3, nonrandomized, open-label study evaluating the pharmacokinetics, efficacy, of pediatric formulation GLE PIB ages 3 to < 12 years.Children with HCV infection, genotype 1-6, or without compensated cirrhosis, divided into three cohorts by age-cohort (9 years), cohort (6 9 4 (3 6 years)-and given weight-based doses for 8, 12, 16...
A prospective observational study to investigate hematologic alterations during the first 3 months of life in HIV-exposed uninfected infants subjected antiretroviral medication before and after birth.Two hundred twenty-one consecutive born HIV-positive mothers on pregnancy were included. Perinatal transmission prophylaxis comprised zidovudine (ZDV) administered intravenously intrapartum 10 days birth. Blood counts differentials determined at birth 2, 4, 6, 12 weeks age, toxicity was graded...
Currently, the only approved hepatitis C virus (HCV) treatment for children aged <12 years is pegylated interferon plus ribavirin. In an open-label study, we evaluated safety and efficacy of sofosbuvir ribavirin 12 weeks in 3 to chronically infected with genotype 2 or 24 patients 3. Patients <6 weighing <17 kg received 150 mg, ≥17 all 6 200 mg once daily. Intensive pharmacokinetic sampling conducted each age group confirmed appropriateness doses. For patients, dosing was determined by...
Rationale In 2016, a new interferon-gamma release assay (IGRA) was introduced, QuantiFERON-TB Gold Plus (QFT-Plus), claimed to have improved sensitivity in active tuberculosis (TB). Objectives This study aimed determine the performance of QFT-Plus, compared with previous generation IGRAs and tuberculin skin test (TST), children TB Europe. Methods Multicentre, ambispective cohort within Paediatric Tuberculosis Network European Trials Group (ptbnet), dedicated paediatric research network...
In Germany tuberculosis is a rare disease and usually well treatable. Worldwide it one of the most common infectious diseases with approximately 10 million new cases every year. Even low incidences in Germany, an important differential diagnosis especially due to international developments migration movements. With decreasing experience there's continuous demand on accurate up-to-date information. This guideline covers all aspects microbiological diagnostics, basic principles standard...
To compare the immunogenicity and safety of a virosome-adjuvanted influenza vaccine (Inflexal V; Berna Biotech, Berne, Switzerland) split (Fluarix; GlaxoSmithKline Biologicals, Rixensart, Belgium) in children.The subjects, 453 children ages 6 to 71 months, were stratified into primed unprimed age groups (6 35 36 months) then randomized 1:1 receive (n = 224) or 229), half full dose was given intramuscularly according age. Unprimed received second after 4 weeks. Blood samples 326) collected...
To describe the long-term efficacy over 5 years of regimens including combinations abacavir, lamivudine and/or zidovudine in previously untreated children PENTA trial.PENTA was a 48-week randomised controlled trial comparing three dual nucleoside reverse transcriptase inhibitor (NRTI) as part first triple antiretroviral therapy (ART).128 ART-naïve were to zidovudine\lamivudine (n = 36), zidovudine\abacavir (45) or lamivudine\abacavir (47). Asymptomatic 55) also nelfinavir placebo; all other...
Recently, epidemiological data shows an increase of childhood tuberculosis in Germany. In addition to this, drug resistant becomes more frequent. Therefore, diagnosis, prevention and therapy adolescence remain a challenge. Adult guidelines do not work for children, as there are age specific differences manifestation, risk progression diagnostic well therapeutic pathways.The German Society Pediatric Infectious Diseases (DGPI) has initiated consensus-based (S2k) process completed paediatric...
Abstract Objectives Global guidelines increasingly support breastfeeding among women living with HIV (WLWH) under optimized conditions. However, outcome data from high-resource settings remain limited. Methods We retrospectively analyzed WLWH who delivered at Charité – Universitätsmedizin Berlin between 2017 and 2023. Eligibility for required VL<50 cop/mL. Results Of 409 WLWH, 365 (89.2 %) were eligible 77 (18.8 initiated breastfeeding. No case of mother-to-child transmission (MTCT) was...
Breastfeeding (BF) in mothers living with HIV (MLWH) is still discussed controversially resource-rich settings. In Germany, where formula feeding recommended for MLWH single BF cases have been reported, but no systematic data collection and analysis are available so far. This study, titled HELENE, aims to fill this gap. A questionnaire covering the course of was distributed by a graduate student visiting each study site. Information collected from patient files personal communication health...
To investigate zidovudine prophylaxis with caesarean section to reduce mother-to-infant HIV transmission.Elective before labour, usually at 36-38 weeks of gestation, plus a short oral course zidovudine, normally starting week 32, intravenous and for 10 days the neonate (the reduced Berlin regimen).Of 179 mother-infant pairs 104 received no antiretroviral or therapy (control group), 48 regimen, 18 combination nine only part regimen. Of group, 68 were delivered by elective section. The...
Abstract Background In high-resource settings, the survival of children with immunocompromise (IC) has increased and immunosuppressive therapies are increasingly being used. This study aimed to determine clinical characteristics, performance diagnostic tools, outcome IC tuberculosis (TB) in Europe. Methods Multicenter, matched case-control within Pediatric Tuberculosis Network European Trials Group, capturing TB cases &lt;18 years diagnosed 2000–2020. Results A total 417 were included,...
Background Granulysin produced by cytolytic T cells directly contributes to immune defense against tuberculosis (TB). We investigated granulysin as a candidate marker for childhood and adolescent TB. Methods Peripheral blood mononuclear (PBMC) from children adolescents (1–17 years) with active TB, latent TB infection (LTBI), nontuberculous mycobacteria (NTM) uninfected controls were isolated restimulated in 7-day restimulation assay. Intracellular staining was then performed analyze...
Abstract Introduction Antiretroviral therapy (ART) is integral to HIV prevention, including averting vertical transmission. The World Health Organization (WHO) recommends ART and breastfeeding for all women living with at least 12 months post‐partum [1, 2]. Much of the data on transmission through comes from low‐resource settings, a paucity breastfeeding‐related in other settings. Women Against Viruses Europe (WAVE), part European AIDS Clinical Society (EACS), aims improve standard care...
Patients infected with human immunodeficiency virus type 1 (HIV-1) are considered to be at increased risk for 2009 H1N1 influenza-related complications. We performed an observational study after outbreak of influenza infection among a group 15 HIV-1-infected school-aged children in Germany October 2009. Clinical course, kinetics viral shedding, and antibody response CD4 cell counts >350 cells/μL coinfection did not appear differ from that healthy children. Oseltamivir shortened the duration shedding.
In 2015, 4062 unaccompanied minor refugees were registered in Berlin, Germany. According to national policies, basic clinical examination and tuberculosis (TB) screening is a prerequisite admission permanent accommodation schooling for every refugee. This article evaluates the use of an interferon-γ-release-assay (IGRA) during initial TB 970 refugees.IGRA test obtained 301 (31.0%) adolescents not previously screened TB. Positive IGRA results 13.9% (42/301). Most 42 IGRA-positive originated...
To evaluate the pharmacokinetics, weight-based dose selection and short-term safety tolerability of etravirine in HIV-1-infected children adolescents.Phase I, nonrandomized, open-label study two stages.Children adolescents aged at least 6 years to 17 or less on a stable lopinavir/ritonavir-based antiretroviral regimen with HIV-1 RNA plasma viral load than 50 copies/ml were enrolled. In both stages, (4 mg/kg twice daily stage 5.2 II), added existing regimen, was administered for 7 days...